112 related articles for article (PubMed ID: 29927371)
1. Ribavirin-induced mutagenesis across the complete open reading frame of hepatitis C virus genotypes 1a and 3a.
Mejer N; Fahnøe U; Galli A; Ramirez S; Benfield T; Bukh J
J Gen Virol; 2018 Aug; 99(8):1066-1077. PubMed ID: 29927371
[TBL] [Abstract][Full Text] [Related]
2. Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model.
Galli A; Mens H; Gottwein JM; Gerstoft J; Bukh J
Sci Rep; 2018 Mar; 8(1):4619. PubMed ID: 29545599
[TBL] [Abstract][Full Text] [Related]
3. Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir.
Ramirez S; Mikkelsen LS; Gottwein JM; Bukh J
Gastroenterology; 2016 Nov; 151(5):973-985.e2. PubMed ID: 27453546
[TBL] [Abstract][Full Text] [Related]
4. Influence of amino acid variations in the NS3, NS4A and NS4B of HCV genotypes 1a, 1b, 3a, 3b and 6f on the response to pegylated interferon and ribavirin combination therapy.
Chusri P; Kumthip K; Pantip C; Thongsawat S; O'Brien A; Maneekarn N
Virus Res; 2015 Jan; 196():37-43. PubMed ID: 25445343
[TBL] [Abstract][Full Text] [Related]
5. Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity.
Mejer N; Fahnøe U; Galli A; Ramirez S; Weiland O; Benfield T; Bukh J
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928732
[TBL] [Abstract][Full Text] [Related]
6. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy.
Young KC; Lindsay KL; Lee KJ; Liu WC; He JW; Milstein SL; Lai MM
Hepatology; 2003 Oct; 38(4):869-78. PubMed ID: 14512874
[TBL] [Abstract][Full Text] [Related]
7. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA.
Pfeiffer JK; Kirkegaard K
J Virol; 2005 Feb; 79(4):2346-55. PubMed ID: 15681435
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy.
Kadokura M; Maekawa S; Sueki R; Miura M; Komase K; Shindo H; Amemiya F; Uetake T; Inoue T; Sakamoto M; Nakagawa M; Sakamoto N; Watanabe M; Enomoto N
PLoS One; 2011; 6(9):e24514. PubMed ID: 21935415
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.
Ciesek S; Proske V; Otto B; Pischke S; Costa R; Lüthgehetmann M; Polywka S; Klempnauer J; Nashan B; Manns MP; von Hahn T; Lohse AW; Wedemeyer H; Mix H; Sterneck M
Transpl Infect Dis; 2016 Jun; 18(3):326-32. PubMed ID: 26988272
[TBL] [Abstract][Full Text] [Related]
10. Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin.
Rower JE; Meissner EG; Jimmerson LC; Osinusi A; Sims Z; Petersen T; Bushman LR; Wolfe P; McHutchison JG; Kottilil S; Kiser JJ
J Antimicrob Chemother; 2015 Aug; 70(8):2322-9. PubMed ID: 25971261
[TBL] [Abstract][Full Text] [Related]
11. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
Iqbal S; Yousuf MH; Yousaf MI
World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
[TBL] [Abstract][Full Text] [Related]
12. [Genomic diversity of the genotype 1b hepatitis C virus open reading frame is correlated with outcomes of combined pegylated-interferon/ribavirin therapy in patients with chronic hepatitis C from Henan Province].
Zeng Y; Kang Y; Shang J
Zhonghua Gan Zang Bing Za Zhi; 2014 Jun; 22(6):401-6. PubMed ID: 25203700
[TBL] [Abstract][Full Text] [Related]
13. Identification of hepatitis C virus genotype 2a replicon variants with reduced susceptibility to ribavirin.
Hmwe SS; Aizaki H; Date T; Murakami K; Ishii K; Miyamura T; Koike K; Wakita T; Suzuki T
Antiviral Res; 2010 Mar; 85(3):520-4. PubMed ID: 20043953
[TBL] [Abstract][Full Text] [Related]
14. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
[TBL] [Abstract][Full Text] [Related]
15. Ribavirin inhibition of cell-culture infectious hepatitis C genotype 1-3 viruses is strain-dependent.
Mejer N; Galli A; Ramirez S; Fahnøe U; Benfield T; Bukh J
Virology; 2020 Jan; 540():132-140. PubMed ID: 31778898
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
Tao T; Jiang X; Chen Y; Song Y
Int J Infect Dis; 2017 Feb; 55():56-71. PubMed ID: 28040553
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of Hepatitis C Virus Genotypes in Pakistan: Current Scenario and Review of Literature.
Haqqi A; Munir R; Khalid M; Khurram M; Zaid M; Ali M; Shah ZH; Ahmed H; Afzal MS
Viral Immunol; 2019 Nov; 32(9):402-413. PubMed ID: 31556811
[TBL] [Abstract][Full Text] [Related]
18. Inosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C Virus.
Nyström K; Wanrooij PH; Waldenström J; Adamek L; Brunet S; Said J; Nilsson S; Wind-Rotolo M; Hellstrand K; Norder H; Tang KW; Lagging M
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045981
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C.
Rivero-Juarez A; Brieva T; Frias M; Rivero A
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):901-910. PubMed ID: 30058394
[TBL] [Abstract][Full Text] [Related]
20. Establishment of hepatitis C virus RNA-replicating cell lines possessing ribavirin-resistant phenotype.
Satoh S; Mori K; Ueda Y; Sejima H; Dansako H; Ikeda M; Kato N
PLoS One; 2015; 10(2):e0118313. PubMed ID: 25699517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
